Meeting
2023 ASCO Annual Meeting
INTRAMET: Results of a prospective, single-arm, open-label phase II trial of intraoperative radiotherapy after resection of brain metastases.
Authors
Stefanie Brehmer
Department of Neurosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Stefanie Brehmer , Gustavo R Sarria , Sara Würfel , Ardita Sulejmani , Frank Schneider , Sven Clausen , Arne Mathias Ruder , Elena Sperk , Nima Etminan , Frank Anton Giordano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Clinical Trial Registration Number
NCT03226483
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2031)
DOI
10.1200/JCO.2023.41.16_suppl.2031
Abstract #
2031
Poster Bd #
388
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).
First Author: Changhoon Yoo
Poster
2022 ASCO Annual Meeting
IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.
First Author: Anna Saborowski
Poster
2022 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes of patients managed with surgical resection of brain metastasis from renal cell carcinoma.
First Author: Max Drescher
